title: The consequences of genetic and pharmacologic reduction in sphingolipid synthesis.
abstract: A new therapy based on substrate synthesis reduction in sphingolipidoses is showing promise. The consequences of decreasing sphingolipid synthesis depend on the level at which synthetic blockage occurs and on the extent of the blockage. Complete synthetic blockage may be lethal if it includes all sphingolipids, such as in a global knockout of serine palmitoyltransferase. Partial inhibition of sphingolipid synthetic pathways is usually benign and may have beneficial effects in a number of lysosomal diseases and in more common pathologies, as seen in animal models for atherosclerosis, polycystic kidney disease, diabetes, and asthma. Studies of various forms of sphingolipid synthesis reduction serve to highlight not only the cellular role of these lipids but also the potential risks and therapeutic benefits of pharmacological agents to be used in therapy for human diseases.
authors.affiliation: Institute of Metabolic Disease, Baylor Research Institute, 3812 Elm Street, Dallas, TX, USA, raphael.schiffmann@baylorhealth.edu.
authors.forename: Raphael
authors.initials: R
authors.lastname: Schiffmann
mesh_terms: D000818:Animals; D001249:Asthma / Q000235:genetics; D050197:Atherosclerosis / Q000235:genetics; D003920:Diabetes Mellitus / Q000235:genetics; D004195:Disease Models, Animal; D005947:Glucose / Q000737:chemistry; D005964:Glucosyltransferases / Q000235:genetics; D006801:Humans; D050356:Lipid Metabolism / Q000235:genetics*; D008247:Lysosomes / Q000378:metabolism; D051379:Mice; D007690:Polycystic Kidney Diseases / Q000235:genetics; D051102:Serine C-Palmitoyltransferase / Q000235:genetics; D013106:Sphingolipidoses / Q000235:genetics; D013107:Sphingolipids / Q000096:biosynthesis*; D014530:Uridine Diphosphate / Q000737:chemistry
chemical_list: D013107:Sphingolipids; D014530:Uridine Diphosphate; D051102:Serine C-Palmitoyltransferase; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase; D005947:Glucose